References
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
- Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380 - 4; http://dx.doi.org/10.1038/35077246; PMID: 11357146
- Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263 - 74; http://dx.doi.org/10.1038/nrc1586; PMID: 15776005
- Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485 - 92; http://dx.doi.org/10.1056/NEJM198512053132327; PMID: 3903508
- Yee C, Greenberg P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2002; 2:409 - 19; http://dx.doi.org/10.1038/nrc820; PMID: 12189383
- Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 2013; 123:4479 - 88; http://dx.doi.org/10.1172/JCI69589; PMID: 24091329
- Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297 - 308; http://dx.doi.org/10.1016/j.ccr.2012.02.014; PMID: 22439925
- Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 2013; 12:152; http://dx.doi.org/10.1186/1476-4598-12-152; PMID: 24298908
- Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9:425 - 34; http://dx.doi.org/10.1016/j.ccr.2006.04.023; PMID: 16766262
- Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 2011; 89:205 - 12; http://dx.doi.org/10.1007/s00109-011-0730-x; PMID: 21301795
- Ohashi T, Akazawa T, Aoki M, Kuze B, Mizuta K, Ito Y, Inoue N. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer 2013; 133:1107 - 18; http://dx.doi.org/10.1002/ijc.28114; PMID: 23420584
- Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012; 72:2746 - 56; http://dx.doi.org/10.1158/0008-5472.CAN-11-1272; PMID: 22593198
- Bénéteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, Marchetti S, Cornille A, Carles M, Ricci JE. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl Acad Sci U S A 2012; 109:20071 - 6; http://dx.doi.org/10.1073/pnas.1206360109; PMID: 23169636
- Kareva I, Hahnfeldt P. The emerging “hallmarks” of metabolic reprogramming and immune evasion: distinct or linked?. Cancer Res 2013; 73:2737 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-12-3696; PMID: 23423980